Michael Pourdehnad
About Michael Pourdehnad
Michael Pourdehnad is the Vice President of Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb and a Clinical Assistant Professor at UCSF Medical Center. He has extensive experience in hematologic malignancies, bone marrow transplantation, and early clinical development in hematology, oncology, and cell therapy.
Current Position at Bristol Myers Squibb
Michael Pourdehnad is the Vice President of Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb. Based in San Francisco, California, he started this role in November 2019. His responsibilities include overseeing early clinical trials and development strategies for hematologic malignancies and cell therapies.
Current Role at UCSF Medical Center
As a Clinical Assistant Professor in Hematology and Oncology at UCSF Medical Center, Michael Pourdehnad contributes to both academic and clinical education. His role involves mentoring students, conducting research, and providing clinical care, particularly focusing on hematologic malignancies and bone marrow transplantation.
Previous Experience at Celgene
From 2013 to 2019, Michael Pourdehnad worked at Celgene as the Executive Director of Translational Development for Hematology/Oncology. During his six-year tenure in the San Francisco Bay Area, he was involved in leading the transition of groundbreaking therapies from laboratory research to clinical application.
Educational Background
Michael Pourdehnad earned his MD from Chicago Medical School at Rosalind Franklin University of Medicine and Science, completing his studies in 2005. He later pursued post-doctoral research in mRNA translation control in cancer at the University of California, San Francisco, from 2011 to 2013.
Early Career and Research Experience
Michael Pourdehnad began his research career as a Research Specialist at the University of Pennsylvania, where he worked from 1997 to 2001. He later served as Chief Resident at Mount Sinai Medical Center from 2005 to 2009. These roles provided foundational experience in medical research and clinical leadership.